GlassScriptPhysician profile
Vicki L Moore
NPI 1942349220
$9,394.97
in general payments reported to CMS, 2019-2025
48 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $987 · 2021: $1,248 · 2022: $1,214 · 2023: $1,454 · 2024: $1,857 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,841.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,673.45 | 2019-2025 | |
| Novo Nordisk INC | $1,470.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $962.44 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $776.78 | 2021-2025 | |
| Lilly USA, LLC | $603.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $514.85 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Abbott Laboratories | $510.21 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $290.42 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $281.51 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.20 | 2019-2024 | Jardiance |
| Eisai INC. | $209.79 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.43 | 2020-2025 | Xifaxan |
| Exact Sciences Corporation | $159.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $154.61 | 2019-2021 | |
| Astellas Pharma US INC | $124.33 | 2019-2024 | Veozah, Myrbetriq |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.